Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

NCT ID: NCT03463265

Last Updated: 2023-11-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 62 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-01
• Study Completion Date: 2022-08-26

Brief Summary

Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was administered as single agent or in combination therapies.

Detailed Description

A phase 2, open-label study of nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was administered as single agent or in combination therapies, including temozolomide, bevacizumab, lomustine, and marizomib.

Conditions

High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A, Cohort 1: nab-sirolimus in patients with recurrent high grade glioma

nab-Sirolimus (ABI-009, nab-rapamycin, albumin-bound rapamycin) was administered at 100 mg/m2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle.

Group Type: EXPERIMENTAL

nab-sirolimus

Intervention Type: DRUG

nab-sirolimus, single agent

Arm A, Cohort 2: nab-sirolimus + temozolomide (TMZ) in patients with recurrent high grade glioma

nab-Sirolimus (60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle).

Temozolomide (PO at 50 mg/m2 daily)

Group Type: EXPERIMENTAL

nab-sirolimus + temozolomide

Intervention Type: DRUG

temozolomide, combination

Arm A, Cohort 3: nab-sirolimus + bevacizumab in patients with recurrent high grade glioma

nab-Sirolimus (IV 60 mg/m 2 as a 30-minute infusion on Days 1, 8, and 15 of every 28-day cycle).

Bevacizumab (IV at a fixed dose of 5 mg/kg on Days 1 and 15 of every 28-day cycle).

Group Type: EXPERIMENTAL

nab-sirolimus + bevacizumab

Intervention Type: DRUG

bevacizumab, combination

Arm A, Cohort 4: nab-sirolimus + lomustine (CCNU) in patients with recurrent high grade glioma

nab-Sirolimus was administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1 and 8 of every 21-day cycle.

CCNU was administered PO at 90 mg/m2 on Day 1 of each odd 21-day cycle (ie, every 6 weeks).

Group Type: EXPERIMENTAL

nab-sirolimus + lomustine

Intervention Type: DRUG

lomustine, combination

Arm A, Cohort 5: nab-sirolimus + marizomib (MRZ) in patients with recurrent high grade glioma

nab-Sirolimus was administered at 60 mg/m 2 as a 30-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle.

MRZ was administered at 0.8 mg/m 2 as a 10-minute IV infusion on Days 1, 8, and 15 of every 28-day cycle. MRZ was administered approximately 10 minutes after the end of the nab-sirolimus infusion.

Group Type: EXPERIMENTAL

nab-sirolimus + marizomib (MRZ)

Intervention Type: DRUG

marizomib (MRZ), combination

Arm B: nab-sirolimus + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma

Induction Treatment (4 weeks) with nab-sirolimus (60 mg/m2 IV weekly); followed by

Concomitant Treatment (standard of care; 2 cycles): nab-sirolimus (60 mg/m2 IV on Days 8 and 15 of every 21-day cycle) in combination with TMZ (75 mg/m2 PO daily for 6 weeks) + radiotherapy (30 × 200 cGy, 5 days/week); followed by

Adjuvant Treatment (6 cycles) starting 4 weeks after Concomitant Treatment, with nab-sirolimus(60 mg/m2 IV on Days 1, 8, and 15 of every 28-day cycle) in combination with TMZ (150 mg/m2 PO daily on Days 1-5 of every 28-day cycle)

Group Type: EXPERIMENTAL

nab-sirolimus + temozolomide + radiotherapy

Intervention Type: DRUG

temozolomide + radiotherapy, combination

Interventions

nab-sirolimus

nab-sirolimus, single agent

Intervention Type: DRUG

nab-sirolimus + temozolomide

temozolomide, combination

Intervention Type: DRUG

nab-sirolimus + bevacizumab

bevacizumab, combination

Intervention Type: DRUG

nab-sirolimus + lomustine

lomustine, combination

Intervention Type: DRUG

nab-sirolimus + marizomib (MRZ)

marizomib (MRZ), combination

Intervention Type: DRUG

nab-sirolimus + temozolomide + radiotherapy

temozolomide + radiotherapy, combination

Intervention Type: DRUG

Other Intervention Names

nab-sirolimus; temozolomide; nab-sirolimus; bevacizumab; nab-sirolimus; lomustine (CCNU); nab-sirolimus; marizomib (MRZ); nab-sirolimus; temozolomide; radiation

Eligibility Criteria

Inclusion Criteria

1. All subjects must have histologic evidence of high grade glioma (World Health Organization [WHO] grade 3 or grade 4) and radiographic evidence of recurrence or disease progression (defined as either a greater than 25% increase in the largest bi-dimensional product of enhancement, a new enhancing lesion, or a significant increase in T2 FLAIR). Subjects must have at least 1 measurable lesion by RANO criteria (≥ 10 mm in 2 perpendicular diameters).

2. Patients must have previously failed a treatment regimen, including radiation and/or chemotherapy.

3. No prior treatment with mTOR inhibitors.

4. No prior treatment with temozolomide for the treatment of recurrent glioma for patients entering the ABI-009 + temozolomide cohort.

5. No prior treatment with bevacizumab or any other anti-angiogenic agents, including sorafenib, sunitinib, axitinib, pazopanib, or cilengitide for the ABI-009 + bevacizumab arm.

6. No prior treatment with lomustine for the ABI-009 + lomustine arm.

7. No prior treatment with marizomib or any other proteasome inhibitors, including bortezomib, carfilzomib, or ixazomib, for patients entering the ABI-009 + marizomib cohort.

8. At least 4 weeks from surgical resection and at least 12 weeks from the end of radiotherapy prior to enrollment in this study, unless relapse is confirmed by tumor biopsy or new lesion outside of radiation field, or if there are two MRIs confirming progressive disease that are approximately 4 weeks apart.

1. Histologically confirmed newly diagnosed glioblastoma.

2. Patients must have had surgery and can have either non-measurable disease or a measurable post-contrast lesion after surgery detected by MRI.

3. No prior treatment with mTOR inhibitors, and no prior local or systemic therapy for GBM.

Exclusion Criteria

A patient will not be eligible for inclusion in this study if any of the following criteria apply:

1. Co-medication or concomitant therapy that may interfere with study results, including anti-coagulants and enzyme-inducing anti-epileptic drugs (EIAEDs).

2. History of thrombotic or hemorrhagic stroke or myocardial infarction within 6 months.

3. Pregnant or breast feeding.

4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics & psychiatric illness/social situations that would limit compliance with study requirements, or disorders associated with significant immunocompromised state.

5. Active gastrointestinal bleeding.

6. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥90 mm Hg.

7. Patients with history of intestinal perforations, fistula, hemorrhages and/or hemoptysis ≤6 months prior to first study treatment.

8. Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy.

9. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.

10. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to receiving the first dose of ABI-009.

11. Known other previous/current malignancy requiring treatment within ≤ 3 years except for limited disease treated with curative intent, such as in situ prostate cancer, intracapsular renal cancer, cervical carcinoma in situ, squamous or basal cell skin carcinoma, and superficial bladder carcinoma.

12. Any comorbid condition that restricts the use of study drug and confounds the ability to interpret data from the study as judged by the Investigator or Medical Monitor.

13. Known Human Immunodeficiency Virus (HIV), or active Hepatitis B or Hepatitis C.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aadi Bioscience, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

St. Joseph Heritage Healthcare

Fullerton, California, United States

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

John Wayne Cancer Institute

Santa Monica, California, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

GBM-007

Identifier Type: -

Identifier Source: org_study_id